The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11033 malaria professionals are enjoying the free benefits of MalariaWorld today


Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Mali: a systematic review and meta-analysis

September 1, 2021 - 16:38 -- Open Access
Fatoumata O. Maiga, Mamadou Wele, Jeffrey G. Shaffer, et al.
Malaria Journal 2021 20:356, 30 August 2021

Artemisinin-based combination therapy (ACT) was deployed in 2005 as an alternative to chloroquine and is considered the most efficacious treatment currently available for uncomplicated falciparum malaria. While widespread artemisinin resistance has not been reported to date in Africa, recent studies have reported partial resistance in Rwanda. The purpose of this study is to provide a current systematic review and meta-analysis on ACT at Mali study sites, where falciparum malaria is highly endemic.

Cardiopulmonary alterations by ultrasound in a patient with uncomplicated mixed malaria infection: a case report from the Amazon Basin

July 28, 2021 - 15:30 -- Open Access
Alma Wegener, Karine O. Lima, Philip Brainin, et al.
Malaria Journal 2021 20:330, 28 July 2021

Information on cardiopulmonary complications in clinical malaria is sparse and diagnosis may be difficult in resource-limited areas due to lack of proper diagnostic tools and access to medical care. A case of pericardial effusion and pulmonary alterations assessed by ultrasound in a patient with uncomplicated mixed malaria infection is described.

Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria

June 29, 2021 - 14:18 -- Open Access
Dini S, Zaloumis SG, Price DJ, Gobeau N, Kümmel A, Cherkaoui M, Moehrle JJ, McCarthy JS, Simpson JA
J Antimicrob Chemother. 2021 Jun 28:dkab181

The efficacy of artemisinin-based combination therapies (ACTs), the first-line treatments for uncomplicated falciparum malaria, has been declining in malaria-endemic countries due to the emergence of malaria parasites resistant to these compounds. Novel alternative therapies are needed urgently to prevent the likely surge in morbidity and mortality due to failing ACTs.

Progress and challenges of integrated drug efficacy surveillance for uncomplicated malaria in Thailand

June 16, 2021 - 12:34 -- Open Access
Prayuth Sudathip, Aungkana Saejeng, Jui A. Shah, et al.
Malaria Journal 2021 20:261, 9 June 2021

Integrated drug efficacy surveillance (iDES) was formally introduced nationally across Thailand in fiscal year 2018 (FY2018), building on a history of drug efficacy monitoring and interventions. According to the National Malaria Elimination Strategy for Thailand 2017–2026, diagnosis is microscopically confirmed, treatment is prescribed, and patients are followed up four times to ensure cure.

Care-seeking behaviour and socio-economic burden associated with uncomplicated malaria in the Democratic Republic of Congo

June 16, 2021 - 12:32 -- Open Access
Nadine Kalenda Kayiba, Doudou Malekita Yobi, Niko Speybroeck, et al.
Malaria Journal 2021 20:260, 9 June 2021

This study aimed to estimate the socio-economic costs of uncomplicated malaria and to explore health care-seeking behaviours that are likely to influence these costs in the Democratic Republic of Congo (DRC), a country ranked worldwide as the second most affected by malaria.

Genetic diversity and genetic relatedness in Plasmodium falciparum parasite population in individuals with uncomplicated malaria based on microsatellite typing in Eastern and Western regions of Uganda, 2019–2020

June 5, 2021 - 06:24 -- Open Access
Agaba B. Bosco, Karen Anderson, Qin Cheng, et al.
Malaria Journal 2021 20:242, 31 May 2021

Genetic diversity and parasite relatedness are essential parameters for assessing impact of interventions and understanding transmission dynamics of malaria parasites, however data on its status in Plasmodium falciparum populations in Uganda is limited. Microsatellite markers and DNA sequencing were used to determine diversity and molecular characterization of P. falciparum parasite populations in Uganda.

Hematological indices and abnormalities among patients with uncomplicated falciparum malaria in Kosti city of the White Nile state, Sudan: a comparative study

June 1, 2021 - 15:47 -- Open Access
Elkhalifa AME, Abdul-Ghani R, Tamomh AG, Eltaher NE, Ali NY, Ali MM, Bazie EA, KhirAlla A, DfaAlla FA, Alhasan OAM
BMC Infect Dis. 2021 May 31;21(1):507

Hematological abnormalities are common features in falciparum malaria but vary among different populations across countries. Therefore, we compared hematological indices and abnormalities between Plasmodium falciparum-infected patients and malaria-negative subjects in Kosti city of the White Nile State, Sudan.

Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis

April 14, 2021 - 16:50 -- Open Access
Shibeshi W, Alemkere G, Mulu A, Engidawork E
BMC Infect Dis. 2021 Apr 7;21(1):326

Malaria is a major cause of morbidity and mortality in pediatrics in malaria endemic areas. Artemisinin-based combination therapies (ACTs) are the drugs of choice for malaria management particularly across malaria-endemic countries. This systematic review and meta-analysis was performed to assess efficacy and safety of ACTs for uncomplicated malaria in pediatric populations.

Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso

February 17, 2021 - 09:25 -- Open Access
Siribie M, Tchouatieu AM, Sirima SB, et al.
BMJ Open. 2021 Feb 15;11(2):e040220

As demonstrated in mathematical models, the simultaneous deployment of multiple first-line therapies (MFT) for uncomplicated malaria, using artemisinin-based combination therapies (ACTs), may extend the useful therapeutic life of the current ACTs. This is possible by reducing drug pressure and slowing the spread of resistance without putting patients' life at risk. We hypothesised that a simultaneous deployment of three different ACTs is feasible, acceptable and can achieve high coverage rate if potential barriers are properly identified and addressed.

Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar

February 16, 2021 - 15:49 -- Open Access
Leyre Pernaute-Lau, Ulrika Morris, Mwinyi Msellem, Andreas Mårtensson, Anders Björkman and Jose Pedro Gil
Malaria Journal 2021 20:90, 15 February 2021

The anti-malarial drug, amodiaquine, a commonly used, long-acting partner drug in artemisinin-based combination therapy, is metabolized to active desethyl-amodiaquine (DEAQ) by cytochrome P450 2C8 (CYP2C8). The CYP2C8 gene carries several polymorphisms including the more frequent minor alleles, CYP2C8*2 and CYP2C8*3. These minor alleles have been associated with decreased enzymatic activity, slowing the amodiaquine biotransformation towards DEAQ. This study aimed to assess the influence of these CYP2C8 polymorphisms on the efficacy and tolerability of artesunate–amodiaquine (AS–AQ) treatment for uncomplicated Plasmodium falciparum malaria in Zanzibar.


Subscribe to RSS - uncomplicated